AJO LP lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1,364.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,700,302 shares of the company’s stock after buying an additional 1,584,176 shares during the quarter. AJO LP owned about 0.16% of Eli Lilly and worth $139,935,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of LLY. Heritage Trust Co bought a new position in Eli Lilly and in the first quarter valued at approximately $135,000. Point72 Asia Hong Kong Ltd lifted its stake in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares in the last quarter. Shine Investment Advisory Services Inc. bought a new position in Eli Lilly and in the second quarter valued at approximately $148,000. Cornerstone Advisors Inc. lifted its position in shares of Eli Lilly and by 18.4% in the second quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock worth $166,000 after purchasing an additional 313 shares in the last quarter. Finally, Penserra Capital Management LLC lifted its position in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after purchasing an additional 176 shares in the last quarter. Institutional investors own 75.48% of the company’s stock.
A number of equities analysts recently weighed in on LLY shares. Berenberg Bank restated a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a report on Friday, August 4th. BMO Capital Markets reiterated a “sell” rating and issued a $73.00 price objective on shares of Eli Lilly and in a report on Wednesday, August 16th. Oppenheimer Holdings, Inc. downgraded shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective on the stock. in a report on Wednesday, July 26th. Jefferies Group LLC reiterated a “buy” rating and issued a $89.00 price objective on shares of Eli Lilly and in a report on Thursday, August 31st. Finally, Leerink Swann upped their price target on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $89.76.
Eli Lilly and Company (LLY) opened at $82.86 on Tuesday. The stock has a market capitalization of $91,710.21, a P/E ratio of 20.36, a PEG ratio of 1.83 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the prior year, the firm earned $0.88 earnings per share. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. sell-side analysts anticipate that Eli Lilly and Company will post 4.22 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.51%. Eli Lilly and’s dividend payout ratio is currently 98.58%.
In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the company’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 772,003 shares of company stock worth $64,837,441. Insiders own 0.20% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.truebluetribune.com/2017/11/14/eli-lilly-and-company-lly-position-lifted-by-ajo-lp.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.